Eisuke Nagata
Overview
Explore the profile of Eisuke Nagata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
82
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagata E, Takeuchi S, Nakanishi T, Hasegawa Y, Mawatari Y, Nakano H
Chemphyschem
. 2015 Aug;
16(14):3038-43.
PMID: 26268937
To create a new series of mechanofluorochromic materials and to elucidate the mechanism of the phenomenon of mechanofluorochromism, 1-alkanoylaminopyrenes including 1-acetylaminopyrene (AAPy), 1-octanoylaminopyrene (OAPy), and 1-stearoylaminopyren (SAPy) were prepared. It...
2.
Hanada S, Harada M, Abe M, Akiba J, Sakata M, Kwan R, et al.
J Histochem Cytochem
. 2012 Apr;
60(6):475-83.
PMID: 22473941
Mallory-Denk bodies (MDBs) are hepatocyte cytoplasmic inclusions found in several liver diseases and consist primarily of the cytoskeletal proteins, keratins 8 and 18 (K8/K18). Recent evidence indicates that the extent...
3.
Kawaguchi T, Taniguchi E, Morita Y, Shirachi M, Tateishi I, Nagata E, et al.
Liver Int
. 2009 Dec;
30(3):479-86.
PMID: 20040053
Background: Diabetes mellitus is frequently seen in hepatitis C patients and is often treated with antidiabetic agents that increase serum insulin levels. Because insulin is a growth-promoting hormone, antidiabetic agents...
4.
Usefulness of serum hepatic fibrosis markers in the diagnosis of nonalcoholic steatohepatitis (NASH)
Sasaki N, Ueno T, Morita Y, Nagata E, Sata M
Hepatogastroenterology
. 2006 Nov;
53(71):678-81.
PMID: 17086867
Background/aims: In the present study, we examined the usefulness of serum hepatic fibrosis markers for the diagnosis of nonalcoholic steatohepatitis (NASH). Methodology: The subjects were 16 patients with NASH and...
5.
Morita Y, Ueno T, Sasaki N, Kuhara K, Yoshioka S, Tateishi Y, et al.
Alcohol Clin Exp Res
. 2005 Dec;
29(12 Suppl):277S-81S.
PMID: 16385236
Background: This study compared the liver histology of patients with NASH and patients with ASH. Methods: Subjects consisted of 79 patients (41 in the NASH group and 38 in the...
6.
Morita Y, Ueno T, Sasaki N, Tateishi Y, Nagata E, Kage M, et al.
Hepatogastroenterology
. 2005 Oct;
52(65):1338-43.
PMID: 16201069
Background/aims: In the present study we administered nateglinide to nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes who had failed to respond adequately to diet and exercise therapy, and we...
7.
Kaji R, Sasaki N, Tateishi I, Nagata E, Okabe Y, Yoshida T, et al.
Kurume Med J
. 2003 Sep;
50(1-2):71-5.
PMID: 12971268
Primary hepatic squamous cell carcinoma is rare. In this case, a malignant lesion was detected in bilateral hepatic lobes by ultrasound sonography and computed tomography. The maximum tumor diameter was...
8.
Mizuta Y, Ijyuin H, Ono N, Miyamoto Y, Oho K, Kumashiro R, et al.
Nihon Shokakibyo Gakkai Zasshi
. 2003 Jan;
99(12):1487-92.
PMID: 12518400
No abstract available.